Cardiology

Portal Hypertension

Questions discussed in this category

Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?

1 Answer available

How can hepatic venous pressure gradients in patients with cirrhosis be used to differentiate between cardiac cirrhosis and portopulmonary hypertension?

In which clinical scenario(s) would you consider checking HVPG?

3 Answers available

Papers discussed in this category

Lancet (London, England), 2019 Mar 22

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.

Related Topics in Cardiology